Nexalin Technology (Nexalin Technology) Total Current Liabilities : $0.51 Mil (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Nexalin Technology Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Nexalin Technology's total current liabilities for the quarter that ended in Mar. 2024 was $0.51

Nexalin Technology Total Current Liabilities Historical Data

The historical data trend for Nexalin Technology's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nexalin Technology Total Current Liabilities Chart

Nexalin Technology Annual Data

Trend Dec20 Dec21 Dec22 Dec23

Total Current Liabilities

1.57 2.36 1.95 0.43

Nexalin Technology Quarterly Data

Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24

Total Current Liabilities Get a 7-Day Free Trial 1.20 1.18 1.20 0.43 0.51

Nexalin Technology Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Nexalin Technology's Total Current Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Liabilities = Accounts Payable & Accrued Expense + Short-Term Debt & Capital Lease Obligation

= 0.271 + 0.004

+ Other Current Liabilities + Current Deferred Liabilities

= 0.15 + 0

= 0.43

Nexalin Technology's Total Current Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Current Liabilities = Accounts Payable & Accrued Expense + Short-Term Debt & Capital Lease Obligation

= 0.357 + 0

+ Other Current Liabilities + Current Deferred Liabilities

= 0.15 + 0

= 0.51

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Nexalin Technology Total Current Liabilities Related Terms
Thank you for viewing the detailed overview of Nexalin Technology's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Nexalin Technology (Nexalin Technology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Nexalin Technology Inc (NAS:NXL) » Definitions » Total Current Liabilities

Comparable Companies

DYNT CMXC MHTX HSCS MOTS TNON SINT TIVC VYCO VTAK ABT SYK MDT BSX SZSE:300760 EW DXCM ZBH STE XAMS:PHIA

Traded in Other Exchanges

N/A

Address

1776 Yorktown, Suite 550, Houston, TX, USA, 77056

Website

https://www.nexalin.com

Nexalin Technology Inc design and develop innovative neurostimulation products to uniquely and effectively help combat the ongoing global mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy.

Executives

Marilyn Elson 10 percent owner, officer: Ms. Elson serves as CFO 32 CAMLET COURT, ROSELAND NJ 07068

Rick Morad director 6331 CHAGRIN RIVER ROAD, BENTLEYVILLE OH 44022

Mark White director, officer: President/CEO 1776 YORKTOWN STREET, SUITE 550, HOUSTON TX 77056

David Owens director, officer: Chief Medical Officer 4545 HARRIS TRAIL NW, ATLANTA GA 30327

Alan Kazden director 3435 CONSUELO DRIVE, CALABASAS CA 91302

Leonard Osser other: Spouse

Ben Hu director 7021 EDGERTON ROAD, NORTH ROYALTON OH 44133

Nexalin Technology (Nexalin Technology) Headlines

From GuruFocus

Nexalin Technology Appoints Medical Device Veteran Michael Nketiah as Senior Vice President of Quality, Clinical and Regulatory
By Stock market mentor Stock market mentor • 01-24-2023

Nexalin Technology, Inc. and Wider Come Limited Announce Joint Venture Agreement to Advance Commercialization of Nexalin's tACS Devices in the Asia Pacific Region
By sperokesalga sperokesalga • 06-01-2023

Nexalin Technology Announces Abstract Accepted for Presentation at 2023 Military Health System Research Symposium Validating the Potential of its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device for the Treatment of Mild Traumatic Brain Injury
By Marketwired • 07-10-2023

Nexalin Technology Provides 2022 Year-End Business Update
By sperokesalga sperokesalga • 03-27-2023

Nexalin Technology Announces Publication of a White Paper Validating its tACS Device for the Treatment of Generalized Anxiety Disorder
By Value_Insider Value_Insider • 11-14-2022

Nexalin's CEO Mark White to be Interviewed Live on �The Big Biz Show� Today at 3PM Eastern Time
By Marketwired • 08-03-2023

Nexalin Technology Announces Publication of Groundbreaking Deep-Brain Stimulation Study in Leading Peer-Reviewed Journal; Validates the Ability of Nexalin's Neurostimulation Device to Penetrate Deep Brain Structures
By Marketwired • 10-16-2023

Nexalin Technology Announces New Public Sector Division to Capitalize on Opportunities to Serve U.S. Government Agencies
By Marketwired • 07-26-2023

Nexalin Technology CEO Provides Letter to Shareholders
By Stock market mentor Stock market mentor • 01-05-2023

Nexalin Technology Reports Results of Clinical Study Supporting the Therapeutic Benefits of its Gen-2, 15 Milliamp Neurostimulation Device in Treating Migraine Headaches and Related Symptoms
By Marketwired • 08-07-2023

Nexalin Technology Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Current Liabilities	Get a 7-Day Free Trial									1.20	1.18	1.20	0.43	0.51

Total Current Liabilities	=	Accounts Payable & Accrued Expense	+	Short-Term Debt & Capital Lease Obligation
	=	0.271	+	0.004
	+	Other Current Liabilities	+	Current Deferred Liabilities
	=	0.15	+	0
	=	0.43

Marilyn Elson	10 percent owner, officer: Ms. Elson serves as CFO	32 CAMLET COURT, ROSELAND NJ 07068
Rick Morad	director	6331 CHAGRIN RIVER ROAD, BENTLEYVILLE OH 44022
Mark White	director, officer: President/CEO	1776 YORKTOWN STREET, SUITE 550, HOUSTON TX 77056
David Owens	director, officer: Chief Medical Officer	4545 HARRIS TRAIL NW, ATLANTA GA 30327
Alan Kazden	director	3435 CONSUELO DRIVE, CALABASAS CA 91302
Leonard Osser	other: Spouse
Ben Hu	director	7021 EDGERTON ROAD, NORTH ROYALTON OH 44133